LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Relmada Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERRLMD
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / RLMD COVERAGE

What’s moving Relmada Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2026 Earnings Call Transcript

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2026 Earnings Call Transcript

Investors are testing whether Relmada Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Relmada Therapeutics, Inc. Announces Conference Call to Discuss Q1 2025 Financial Results and Business Progress

Relmada Therapeutics, Inc. Announces Conference Call to Discuss Q1 2025 Financial Results and Business Progress

The story matters when it changes Relmada Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Investors are testing whether Relmada Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
RELMADA ALERT: Bragar Eagel & Squire, P.C. is Investigating Relmada Therapeutics, Inc. on Behalf of Relmada Stockholders and Encourages Investors to Contact the Firm

RELMADA ALERT: Bragar Eagel & Squire, P.C. is Investigating Relmada Therapeutics, Inc. on Behalf of Relmada Stockholders and Encourages Investors to Contact the Firm

Investors are testing whether Relmada Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
What You Need To Know About Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) Investor Composition

What You Need To Know About Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) Investor Composition

The story matters when it changes Relmada Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest RLMD filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-12 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-13 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-19 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-28 · Period 2026-07-28SEC ↗8-KMaterial company eventFiled 2026-05-28 · Period 2026-05-27SEC ↗8-KMaterial company eventFiled 2026-05-12 · Period 2026-05-12SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-17 · Period 2026-05-27SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-07-29SEC ↗
EARNINGS / QUARTERLY TRACKER

Relmada Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.